NASDAQ: OXGN

Home  >   Who We Are  >  Company Info

Company Info

OXiGENE’s business strategy is to identify and in-license compounds complimentary to the Company’s existing pipeline from academic institutions, lead them through clinical trials, and establish partnerships with pharmaceutical and biotechnology companies to further develop, manufacture, and commercialize the compounds. OXiGENE is currently focusing on two market areas, oncology and ophthalmology and is pursing an aggressive development plan to broaden the indication of use for current products and to bring new products into the clinic.

OXiGENE believes this business model:

• Accelerates the drug development cycle
• Broadens the life cycle of products
• Maximizes flexibility in the rapidly changing field of biotechnology
• Utilizes drug discovery development management expertise
• Reduces burn rate

Update Policy   |    Site Usage Terms   |    Copyright & Trademark   |    Privacy Policy   |    Site Map